Vitamin Shoppe, Inc (NYSE:VSI) had its target price decreased by equities research analysts at Morgan Stanley from $7.50 to $4.00 in a research report issued to clients and investors on Thursday. The firm presently has an “equal weight” rating on the specialty retailer’s stock. Morgan Stanley’s price objective indicates a potential upside of 14.29% from the company’s previous close.

Several other analysts also recently commented on the stock. Zacks Investment Research raised shares of Vitamin Shoppe from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 18th. ValuEngine cut shares of Vitamin Shoppe from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Bank of America Corporation restated an “underperform” rating and set a $5.00 target price (down previously from $5.50) on shares of Vitamin Shoppe in a research note on Wednesday, August 23rd. BidaskClub cut shares of Vitamin Shoppe from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Finally, Deutsche Bank AG restated a “hold” rating and set a $7.00 target price (down previously from $14.00) on shares of Vitamin Shoppe in a research note on Thursday, August 10th. Four analysts have rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $5.00.

Shares of Vitamin Shoppe (VSI) opened at $3.50 on Thursday. Vitamin Shoppe has a 1 year low of $2.95 and a 1 year high of $26.60. The company has a market cap of $83.92, a PE ratio of 3.71 and a beta of 0.74. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.34 and a current ratio of 2.07.

Vitamin Shoppe (NYSE:VSI) last announced its quarterly earnings data on Wednesday, November 8th. The specialty retailer reported ($0.03) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.17 by ($0.20). Vitamin Shoppe had a negative net margin of 20.27% and a positive return on equity of 6.17%. The firm had revenue of $288.20 million for the quarter, compared to analysts’ expectations of $297.61 million. During the same period last year, the company posted $0.50 earnings per share. The business’s revenue for the quarter was down 8.5% compared to the same quarter last year. equities analysts predict that Vitamin Shoppe will post 0.72 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Morgan Stanley Lowers Vitamin Shoppe, Inc (VSI) Price Target to $4.00” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/11/11/morgan-stanley-lowers-vitamin-shoppe-inc-vsi-price-target-to-4-00.html.

In other Vitamin Shoppe news, Director John D. Bowlin acquired 40,000 shares of the stock in a transaction dated Friday, August 25th. The shares were purchased at an average price of $5.50 per share, for a total transaction of $220,000.00. Following the purchase, the director now directly owns 56,028 shares of the company’s stock, valued at $308,154. The acquisition was disclosed in a filing with the SEC, which is available at this link. 1.07% of the stock is currently owned by corporate insiders.

Large investors have recently modified their holdings of the company. Schwab Charles Investment Management Inc. lifted its stake in shares of Vitamin Shoppe by 34.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 262,123 shares of the specialty retailer’s stock worth $3,054,000 after purchasing an additional 67,362 shares during the period. Aperio Group LLC bought a new position in shares of Vitamin Shoppe in the 2nd quarter worth approximately $402,000. Teachers Advisors LLC lifted its stake in shares of Vitamin Shoppe by 4.7% in the 1st quarter. Teachers Advisors LLC now owns 63,691 shares of the specialty retailer’s stock worth $1,283,000 after purchasing an additional 2,887 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of Vitamin Shoppe by 16.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 26,788 shares of the specialty retailer’s stock worth $312,000 after purchasing an additional 3,839 shares during the period. Finally, Legal & General Group Plc lifted its stake in shares of Vitamin Shoppe by 9.3% in the 2nd quarter. Legal & General Group Plc now owns 44,555 shares of the specialty retailer’s stock worth $518,000 after purchasing an additional 3,789 shares during the period. Hedge funds and other institutional investors own 98.39% of the company’s stock.

About Vitamin Shoppe

Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.

Analyst Recommendations for Vitamin Shoppe (NYSE:VSI)

Receive News & Stock Ratings for Vitamin Shoppe Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe Inc and related stocks with our FREE daily email newsletter.